Skip to main content

Inlexzo

Pronunciation: inn-lex-zo
Generic name: gemcitabine intravesical system
Brand name: Inlexzo
Dosage form: single-dose intravesical system (225 mg)
Drug class: Antimetabolites

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 10, 2025.

What is Inlexzo? Bladder Cancer Treatment

Inlexzo is used to treat non-muscle invasive bladder cancer (NMIBC) in adults that has not spread to other parts of the body and did not respond to BCG treatment (Bacillus Calmette-Guérin). This innovative intravesical drug delivery system provides targeted gemcitabine therapy directly to bladder cancer cells.

Key Treatment Details:

How Does Inlexzo Bladder Cancer Treatment Work?

Inlexzo is a bladder drug delivery system that is inserted during an outpatient visit. The device stays in the bladder for three weeks and slowly releases gemcitabine chemotherapy directly into the bladder tissue. Patients can receive up to 14 treatment cycles, with each cycle lasting three weeks.

Mechanism of Action - Gemcitabine for Bladder Cancer:

Inlexzo slowly releases gemcitabine, which kills bladder cancer cells by disrupting DNA synthesis. It's converted to active forms that block enzymes needed for DNA building blocks and gets incorporated into DNA itself. This double action enhances gemcitabine's effectiveness (self-potentiation). Once in DNA, it stops further DNA construction, triggering the death of cancer cells.

Clinical Efficacy: BCG-Unresponsive Bladder Cancer Results

SunRISe-1 Clinical Trial Results:

Inlexzo's FDA approval is based on the SunRISe-1 Phase 2b trial (NCT04640623). 82% of patients with BCG-unresponsive NMIBC achieved complete response (no signs of cancer), with 51% maintaining response for at least one year.

Key Clinical Outcomes:

Inlexzo Side Effects - What to Expect During Bladder Cancer Treatment

Most Common Side Effects (≥15% of patients):

Serious Side Effects - Important Safety Information for Bladder Cancer Patients:

Critical Safety Warnings:

For medical advice about side effects, call your healthcare provider or report to the FDA at 1-800-FDA-1088.

Male Fertility and Bladder Cancer Treatment:

Inlexzo may cause fertility problems in males, which may affect your ability to have children. It is unknown if these fertility side effects are reversible. Talk to your healthcare provider if this is a problem for you.

Before Receiving Inlexzo Bladder Cancer Treatment

Absolute Contraindications - Who Cannot Use Inlexzo:

Do not receive Inlexzo if you:

Caution Needed - Medical Conditions and Bladder Cancer Treatment:

Tell your healthcare provider about all of your medical conditions, including if you:

Note: It is not known if Inlexzo is safe and effective for use in children or pediatric bladder cancer.

Pregnancy and Breastfeeding with Bladder Cancer Treatment

Pregnancy Considerations:

Inlexzo can harm your unborn baby. You should not become pregnant during treatment with Inlexzo. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during bladder cancer treatment with Inlexzo.

For females who can become pregnant:

For males treated with Inlexzo:

Breastfeeding Considerations:

It is not known if Inlexzo passes into breastmilk. Do not breastfeed during treatment with Inlexzo and for 1 week after the final removal of Inlexzo.

How is Inlexzo Administered? Bladder Cancer Treatment Schedule

Treatment Protocol:

Pre-Treatment Instructions:

Post-Treatment Care Instructions:

After Device Removal:

MRI Safety with Inlexzo Bladder Cancer Treatment

Important MRI Information: Tell your healthcare provider that you have Inlexzo before having an MRI scan. The device may be used under specific MRI conditions. Your healthcare provider will give you an MRI Safety Information Card. Keep this card safe and show it to all healthcare providers.

Drug Interactions with Bladder Cancer Treatment

Tell your healthcare provider about all medicines you take, including:

Inlexzo Ingredients and Manufacturer Information

Active Ingredient:

Inactive Ingredients:

Gemcitabine component:

Osmotic components:

Manufacturer:

Inlexzo is manufactured by Johnson & Johnson for Janssen Biotech Inc, Horsham, PA 19044, USA.

Frequently Asked Questions About Inlexzo Bladder Cancer Treatment

Is Inlexzo covered by insurance?

Contact your insurance provider to verify bladder cancer treatment coverage for Inlexzo.

How long does Inlexzo treatment last?

Treatment can last up to 2 years with up to 14 cycles total.

Can I drive after Inlexzo insertion?

Most patients can resume normal activities, but follow your healthcare provider's specific instructions.

What if I miss a treatment appointment?

Call your healthcare provider immediately to reschedule - consistent treatment timing is important for bladder cancer therapy effectiveness.

Popular FAQ

Radiation vs. Chemo: Which cancer treatment is right for you?

Chemotherapy treats cancer throughout the body, while radiation targets specific areas. Each approach has unique benefits depending on the type and stage of cancer, as well as your overall health.

Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.